@3speeders @NorthBristolNHS @BladderCancerUK Good luck with your treatment!
#BCGUnresponsive
IBCG - “a clinically meaningful complete response rate for CIS at least 50% at 6m, 30% at 12m..is recommended”
#HIVEC in BCGU
70% CR @ 3m
>50% CR @ 6m
STILL 50% CR @ 12m
https://tinyurl.com/5arewevc
#BladderCancer
#BladderCancerAwarenessMonth
Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
To provide recommendations on appropriate clinical trial designs in non–muscle-invasive bladder cancer (NMIBC) based on current literature and exper...
tinyurl.com
🇵🇱First successful Combat PRS+A-HIPEC Cases after CRS done at the Lower Silesian Oncology Institute in Wroclaw last week🇵🇱 with our local partner Meden-Inmed Sp. z o.o.!
Many thanks to Prof.Dr.Bebenek and his team for the opportunity.@CombatCancer @ESSOnews @operarelcancer #HIPEC
Great results from our friends @DukeUrology on the use of HIVEC in the USA.
“HIVEC is a safe and well-tolerated substitute for BCG during global shortages”
👏🏻👏🏻👏🏻 @DominicGrimberg @BrantInman
#BladderCancer #Cancer #HIVEC
https://www.sciencedirect.com/science/article/abs/pii/S1078143920306542
Intravesical hyperthermia with high-dose mitomycin-C shows promise as BCG alternative for NMIBC
"Our study demonstrates the feasibility of HIVEC MMC and suggests it is a reasonable substitute for BCG during global shortages," says urologist Scott...
www.urologytimes.com
Great results from our friends @DukeUrology on the use of HIVEC in the USA.
“HIVEC is a safe and well-tolerated substitute for BCG during global shortages”
👏🏻👏🏻👏🏻 @DominicGrimberg @BrantInman
#BladderCancer #Cancer #HIVEC
https://www.sciencedirect.com/science/article/abs/pii/S1078143920306542
Intravesical hyperthermia with high-dose mitomycin-C shows promise as BCG alternative for NMIBC
"Our study demonstrates the feasibility of HIVEC MMC and suggests it is a reasonable substitute for BCG during global shortages," says urologist Scott...
www.urologytimes.com
More great news for Combat’s #HIVEC treatment of #bladdercancer from @BrantInman and team at @ASCO meeting.
“Bladder pressure dramatically improves the extent of gemcitabine penetration into the bladder wall”
https://meetinglibrary.asco.org/record/194854/abstract
Many thanks to the team @DukeUrology 👏🏻👏🏻👏🏻
Excellent to hear this. So happy our machine is working to treat patients in Bristol. @CombatCancer #HIVEC #bladdercancer @NorthBristolNHS
Here I go again, this treatment is amazing and I’m so grateful to @NorthBristolNHS #urology for providing this ‘maintenance’ #bladdercancer @CombatCancer @Actionbladderca
Here I go again, this treatment is amazing and I’m so grateful to @NorthBristolNHS #urology for providing this ‘maintenance’ #bladdercancer @CombatCancer @Actionbladderca
@alarjosan @HUReinaSofia @IMIBIC @GECOP_ @operarelcancer @SPeritoneum @aecirujanos @ESSOnews @Hospital_FJD Congrats @alarjosan and team!
Proud to be working with you!
👏🏻👏🏻👏🏻👏🏻👏🏻
Yet another publication showing #HIVEC to be a viable, safe and well tolerated treatment for BCG failure patients with both #mitomycin and #epirubicin.
Thanks to @francescok86 for his great work.
#BladderCancer #Hyperthermia #BCG
https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/125687-outcomes-and-complications-of-hyperthermic-intravesical-chemotherapy-using-mitomycin-c-or-epirubicin-for-patients-with-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-treatment-failure.html
Yet another publication showing #HIVEC to be a viable, safe and well tolerated treatment for BCG failure patients with both #mitomycin and #epirubicin.
Thanks to @francescok86 for his great work.
#BladderCancer #Hyperthermia #BCG
https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/125687-outcomes-and-complications-of-hyperthermic-intravesical-chemotherapy-using-mitomycin-c-or-epirubicin-for-patients-with-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-treatment-failure.html
📢NEXT WEEK📢Prophylactic #peritoneal Management of High-Risk #ColonCancer
🗓️3 NOV-18.30 CEST
🗣Dr @AndreasBrandl8, Dr @alarjosan, Dr Diane Goéré & Dr Pieter Tanis ➡️https://lnkd.in/gNsACYN
#HIPEC #PeritonealMetastases #colorectalsurgery #colorectalcancer @CombatCancer
They don’t do an emoji for HIPEC with agitation bubbles of CO2.
Is this close enough @alarjosan?
🛁🛁🛁🛁🛁
Combat is proud to be sponsoring the Global Congress on Bladder Cancer on the 20th and 21st of September 2018 in Madrid. More Clinical data on HIVEC treatments will be presented during the meeting. For more information see click here or visit us on stand.
